#22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

0 Anmeldelser
0
Episode
23 of 400
Længde
1T 4M
Sprog
Engelsk
Format
Kategori
Personlig udvikling

In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part III, Peter and Tom dig into HDL, why "reverse cholesterol transport" is a lot more nuanced than what most of us are taught, lipid transport, apolipoproteins, and more. In addition, this episode highlights the complexity of HDL and a discussion about the CETP inhibitor trials. We discuss: • Reverse cholesterol transport [1:40]; • Lipid transportation, apolipoproteins, VLDL, IDL, and LDL particles [11:00]; • Remnant lipoproteins and apoC-III [16:45]; • Particles having sex: lipid exchange [28:00]; • Cholesteryl Ester Transfer Protein (CETP) and CETP inhibitors [40:45]; • 2006 CETP inhibitor trial: torcetrapib (Pfizer) [54:45]; • 2012 CETP inhibitor trial: dalcetrapib (Hoffmann–La Roche) [56:15]; • 2017 CETP inhibitor trials: evacetrapib (Eli Lilly) and anacetrapib (Merck) [58:00]; and • More. Learn more at www.PeterAttiaMD.com Connect with Peter on Facebook | Twitter | Instagram.


Lyt når som helst, hvor som helst

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

  • Lyt og læs så meget du har lyst til
  • Opdag et kæmpe bibliotek fyldt med fortællinger
  • Eksklusive titler + Mofibo Originals
  • Opsig når som helst
Prøv nu
DK - Details page - Device banner - 894x1036

Other podcasts you might like ...